This paper presents a mechanistic mathematical model to quantify ERK activity in response to the combined inhibition of BRAF and MEK in BRAFV600E-mutant melanoma. The model, based on mass action kinetics and parameterized with in vitro data, simulates the dynamics of the BRAF-MEK-ERK signaling cascade under the influence of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor). The results show how these drugs synergistically inhibit ERK activity, and how elevated BRAF and ATP levels contribute to drug resistance. The model provides a tool to predict effective drug combinations for treating BRAFV600E-mutated melanoma.
Publisher
British Journal of Cancer
Published On
Oct 07, 2021
Authors
Sara J. Hamis, Yury Kapelyukh, Aileen McLaren, Colin J. Henderson, C. Roland Wolf, Mark A. J. Chaplain
Tags
BRAFV600E-mutant melanoma
ERK activity
BRAF inhibitor
MEK inhibitor
drug resistance
mathematical model
signaling cascade
Related Publications
Explore these studies to deepen your understanding of the subject.